D-serine for Posttraumatic Stress Disorder Treatment
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to asses the effects of the NMDA receptor full agonist D-serine
while used as adjuvant treatment for individuals suffering from chronic posttraumatic stress
disorder (PTSD). Dysfunction of neurotransmission mediated at NMDA receptor plays a cardinal
role in the pathophysiology of PTSD and PTSD patients typically suffer from cognitive
dysfunctions and avoidance& depressive symptomatology that may be mediated by NMDA receptor
function deficits.
Thus, enhancement of NMDA activity by using D-serine may be beneficial in the treatment of
PTSD. The study design involves two 6 week periods during which the participants will be
randomly assigned to receive treatment with D-serine (~2g /dy)and placebo. This design allows
each participant the opportunity to respond to the experimental treatment.